article

The cephalosporins (IPA: ) are a class of β-lactam antibiotics. Together with cephamycins they belong to a sub-group called cephems.

History

Cephalosporin compounds were first isolated from cultures of Cephalosporium acremonium from a sewer in Sardinia in 1948 by Italian scientist Giuseppe Brotzu. He noticed that these cultures produced substances that were effective against Salmonella typhi, the cause of typhoid. Researchers at the Sir William Dunn School of Pathology at the University of Oxford isolated cephalosporin C, which had stability to β-lactamases but was not sufficiently potent for clinical use. The cephalosporin nucleus, 7-aminocephlosporanic acid (7-ACA), was derived from cephalosporin C and proved to be analogous to the penicillin nucleus 6-aminopenicillanic acid. Modification of the 7-ACA side-chains resulted in the development of useful antibiotic agents, and the first agent cephalothin (cefalotin) was launched by Eli Lilly in 1964.

Mode of action

Cephalosporins are bactericidal and have the same mode of action as other beta-lactam antibiotics (such as penicillins). Cephalosporins disrupt the synthesis of the peptidoglycan layer of bacterial cell walls. The peptidoglycan layer is important for cell wall structural integrity, especially in Gram-positive organisms. The final transpeptidation step in the synthesis of the peptidoglycan is facilitated by transpeptidases known as penicillin binding proteins (PBPs).

Clinical use

Indications

Cephalosporins are indicated for the prophylaxis and treatment of bacterial infections caused by susceptible organisms. First-generation cephalosporins are predominantly active against Gram-positive bacteria, and successive generations have increased activity against Gram-negative bacteria (albeit often with reduced activity against Gram-positive organisms).

Adverse effects

Common adverse drug reactions (ADRs) (≥1% of patients) associated with cephalosporin therapy include: diarrhoea, nausea, rash, electrolyte disturbances, and/or pain and inflammation at injection site. Infrequent ADRs (0.1–1% of patients) include: vomiting, headache, dizziness, oral and vaginal candidiasis, pseudomembranous colitis, superinfection, eosinophilia, and/or fever.

Approximately 5–10% of patients with allergic hypersensitivity to penicillins and/or carbapenems will also have cross-reactivity with cephalosporins. Thus, they are contraindicated in patients with a history of severe of immediate allergic reactions (urticaria, anaphylaxis, interstitial nephritis, etc) to penicillins, carbapenems or cephalosporins.Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.

Classification

The cephalosporin nucleus can be modified to gain different properties. Cephalosporins are sometimes grouped into "generations" by their antimicrobial properties. The first cephalosporins were designated first generation while later, more extended spectrum cephalosporins were classified as second generation cephalosporins. Each newer generation of cephalosporins has significantly greater Gram-negative antimicrobial properties than the preceding generation, in most cases with decreased activity against Gram-positive organisms. Fourth generation cephalosporins, however, have true broad spectrum activity.

There is some disagreement on the definition of generations. The fourth generation of cephalosporins is not yet recognized in Japan, and are included in the third generation instead. In Japan, cefaclor is classed as a first generation cephalosporin; and cefbuperazone, cefminox and cefotetan are classed as second generation cephalosporins. Cefbuperazone, cefminox, and cefotetan are classed as second generation cephems. Cefmetazole and cefoxitin are classed as third generation cephems. Flomoxef, latamoxef are in a new class called oxacephems.

Most first generation cephalosporins were originally spelt "ceph-" in English-speaking countries. This continues to be the preferred spelling in North America and Australia, while European countries have adopted International Nonproprietary Names, which are usually spelt "cef-". Newer first-generation cephalosporins and all cephalosporins of later generations are spelt "cef-".

First generation

First generation cephalosporins are moderate spectrum agents, with a spectrum of activity that includes penicillinase-producing, methicillin-susceptible staphylococci and streptococci, though they are not the drugs of choice for such infections. They also have activity against some Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis, but have no activity against Bacteroides fragilis, enterococci, methicilllin-resistant staphylococci, Pseudomonas, Acinetobacter, Enterobacter, indole-positive Proteus or Serratia.

Second generation

The second generation cephalosporins have a greater Gram-negative spectrum while retaining some activity against Gram-positive cocci. They are also more resistant to beta-lactamase.

Second generation cephalosporins with antianaerobe activity

The following cephems are also sometimes grouped with second-generation cephalosporins:

Third generation

Third generation cephalosporins have a broad spectrum of activity and further increased activity against Gram-negative organisms, though with decreased activity against Gram-positive organisms. They may be particularly useful in treating hospital-acquired infections.

Third generation cephalosporins with antipseudomonal activity

The following cephems are also sometimes grouped with third-generation cephalosporins:

Fourth generation

Fourth generation cephalosporins are extended-spectrum agents with similar activity against Gram-positive organisms as first-generation cephalosporins. They also have a greater resistance to beta-lactamases than the third generation cephalosporins. Many can cross blood brain barrier and are effective in meningitis.

The following cephems are also sometimes grouped with third-generation cephalosporins:

Yet to be classified

These cephems have progressed far enough to be named, but have not been assigned to a particular generation. Ceftobiprole (and the oral medocaril version) are on the FDA fast track. Ceftobiprole has powerful antipseudomonal characteristics and appears to be less susceptible to development of resistance.

References

See also

External links

cephalosporin antibiotics

Cephalosporin | Cefalosporina | Céphalosporine | צפלוספורין | セファロスポリン | Cefalosporyny | Cefalosporina | Sefalosporin

 

This article is licensed under the GNU Free Documentation License. It uses material from the "Cephalosporin".

Home Page • arts • business • computers • games • health • hospitals • home • kids & teens • news • physicians • recreation• reference • regional • science • shopping • society • sports • world